---
layout: post
title: "Cover Letter Attachments for Controlled Correspondence and Abbreviated New Drug Application Submissions; Guidance for Industry; Availability"
date: 2026-02-05 18:55:46 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-11943
original_published: 2023-06-06 00:00:00 +0000
significance: 8.00
---

# Cover Letter Attachments for Controlled Correspondence and Abbreviated New Drug Application Submissions; Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 06, 2023 00:00 UTC
**Document Number:** 2023-11943

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cover Letter Attachments for Controlled Correspondence and ANDA Submissions." This guidance is intended to assist prospective applicants, applicants, and holders of abbreviated new drug applications (ANDAs) with optional attachments that can be used when preparing cover letters that accompany controlled correspondence, original ANDAs, amendments to ANDAs, and supplements to approved ANDAs submitted to FDA. This guidance finalizes the draft guidance of the same title issued on December 13, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/06/2023-11943/cover-letter-attachments-for-controlled-correspondence-and-abbreviated-new-drug-application)
- API: https://www.federalregister.gov/api/v1/documents/2023-11943

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
